MCM6 Antibody (D-12): sc-55577

MCM6 Antibody (D-12) is a mouse monoclonal IgG2a antibody that detects MCM6 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). MCM6, a member of the mini-chromosome maintenance (MCM) protein family, plays a crucial role in the regulation of DNA replication, ensuring that DNA is replicated only once during each cell cycle. This regulation is vital for maintaining genomic stability, as improper replication can lead to mutations and cancer. MCM6, along with other MCM proteins, contains an ATP-binding motif that facilitates the opening of double-stranded DNA in an ATP-dependent manner, which is essential for the initiation of DNA replication. The expression of MCM6 is tightly regulated by E2F transcription factors and various protein kinases, which help maintain the postreplicative state of the cell. Notably, MCM6 interacts with other MCM proteins to form a complex that exhibits DNA helicase activity, further underscoring its importance in the replication process. Anti-MCM6 antibody (D-12) is an invaluable tool for researchers studying cell cycle regulation, DNA replication mechanisms, and the implications of MCM proteins in cancer biology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MCM6 Antibody (D-12) References:

1. Cytometry of chromatin bound Mcm6 and PCNA identifies two states in G1 that are separated functionally by the G1 restriction point.  |  Frisa, PS. and Jacobberger, JW. 2010. BMC Cell Biol. 11: 26. PMID: 20398392
2. Methyl(R217)HuR and MCM6 are inversely correlated and are prognostic markers in non small cell lung carcinoma.  |  Vigouroux, C., et al. 2015. Lung Cancer. 89: 189-96. PMID: 26013954
3. MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.  |  Liu, M., et al. 2018. J Exp Clin Cancer Res. 37: 10. PMID: 29357919
4. Ki-67 and MCM6 labeling indices are correlated with overall survival in anaplastic oligodendroglioma, IDH1-mutant and 1p/19q-codeleted: a multicenter study from the French POLA network.  |  Pouget, C., et al. 2020. Brain Pathol. 30: 465-478. PMID: 31561286
5. Methylation-dependent MCM6 repression induced by LINC00472 inhibits triple-negative breast cancer metastasis by disturbing the MEK/ERK signaling pathway.  |  Shao, G., et al. 2021. Aging (Albany NY). 13: 4962-4975. PMID: 33668040
6. De novo MCM6 variants in neurodevelopmental disorders: a recognizable phenotype related to zinc binding residues.  |  Smits, DJ., et al. 2023. Hum Genet. 142: 949-964. PMID: 37198333
7. UBE3A and MCM6 synergistically regulate the proliferation and migration of lung adenocarcinoma cells.  |  Luo, Y., et al. 2023. FEBS Open Bio. 13: 1756-1771. PMID: 37454373
8. MCM6 Inhibits Decidualization via Cross-Talking with ERK Pathway in Human Endometrial Stromal Cells.  |  Jiang, Y., et al. 2024. Reprod Sci. 31: 1915-1923. PMID: 38347378
9. High MCM6 expression promotes proliferation and correlates with poor prognosis in triple-negative breast cancer.  |  Zhang, H., et al. 2024. Eur Rev Med Pharmacol Sci. 28: 2906-2922. PMID: 38639528
10. The MCM6-c-Myc positive feedback loop mediates bladder cancer progression and cisplatin resistance.  |  Wang, J., et al. 2025. Int J Biol Macromol. 296: 139777. PMID: 39805445

The preferred MCM6 antibody is MCM6 Antibody (H-8): sc-393618.